Authors : Pidugu Soudhamini; M. Sreekanth; Venu Talla

Volume/Issue : Volume 10 - 2025, Issue 10 - October

Google Scholar : https://tinyurl.com/msek93b5

Scribd : https://tinyurl.com/ry2s4rhv

DOI : https://doi.org/10.38124/ijisrt/25oct583

Note : A published paper may take 4-5 working days from the publication date to appear in PlumX Metrics, Semantic Scholar, and ResearchGate.

Note : Google Scholar may take 30 to 40 days to display the article.

Abstract : Ulcerative colitis is a chronic inflammatory disorder of the colon that progresses through alternating periods of active flare-ups and remission. The condition primarily affects the lining of the large intestine, beginning in the rectum and often spreading upward through the colon. Several factors can increase susceptibility, including prior bacterial infections such as Salmonella or Campylobacter, as well as a family history of inflammatory bowel disease. Diagnosis is typically guided by clinical symptoms such as rectal bleeding, tenesmus, and an urgent need to defecate. Confirmation is obtained through endoscopic evaluation, which usually reveals continuous mucosal inflammation starting at the rectum and extending proximally, depending on disease severity. Fecal biomarkers may also be utilized to monitor inflammation levels and anticipate relapses. Although ulcerative colitis can severely impact young, otherwise healthy individuals, its underlying causes remain only partially understood. This uncertainty has encouraged diverse theories regarding its development and treatment. Despite significant advances in therapy, the condition continues to pose both clinical and psychological challenges. Treatment strategies are primarily aimed at controlling inflammation and maintaining remission. Commonly prescribed medications include 5-aminosalicylic acid compounds and corticosteroids, with the choice of agent and delivery method based on disease extent and severity. Experimental options such as fecal microbiota transplantation are under investigation, while complementary interventions like probiotics and curcumin have produced variable results. In cases of severe or treatment-resistant disease, surgical management may become necessary. Because prolonged inflammation and immunosuppressive therapy can elevate the risk of colorectal cancer, patients require vigilant preventive care and regular screening to detect complications early.

Keywords : Ulcerative Colitis, Symptoms, Advancements, Treatment.

References :

1. Kucharzik T, Dignass AU, Atreya R, et al.( August 2019 – AWMF Registriernummer 021 – 009). Z Gastroenterol 2019; 57 1321 – 405.
2. Abdulrazeg O, Li B, Epstein J, Guideline Management of ulcerative colitis summary of  streamlined NICE guidance. BMJ 2019; 367 l5897.
3. Maaser C, Petersen F, Helwig U, et al. Intestinal ultrasound for covering  remedial response in cases with ulcerative colitis results from the TRUST&UC study. Gut 2019; gutjnl- 2019 – 319451. Online ahead of print.
4. Wittig R, Albers L, Koletzko S, Saam J, Kries caravan Pediatric  habitual  seditious bowel  complaint in a German statutory health INSURANCE – prevalence rates from 2009 – 2012. J Pediatr Gastroenterol Nutr 2019; 68 244 – 50.
5. Bonovas S, Lytras T, Nikolopoulos G, Peyrin- Biroulet L, Danese S Methodical re view with network meta- analysis  relative assessment of tofacitinib and biologi cal  curatives for moderate- to-severe ulcerative colitis. nourishment Pharmacol Ther 2018; 47 454 – 65.
6. Singh S, Fumery M, Sandborn WJ, Murad MH Methodical review with network meta- analysis first- and alternate- line pharmacotherapy for moderate-severe ulcerative colitis. nourishment Pharmacol Ther 2018; 47 162 – 75.
7. Harbord M, Eliakim R, Bettenworth D, et al. Third European Evi dence- grounded Consensus on  opinion and  operation of ulcerative colitis. Part 2 Current operation. J Crohns Colitis 2017; 11 769 – 84.
8. Gomollon F, Dignass A, Annese V, et al. 3rd European  substantiation- grounded  agreement on the  opinion and  operation of crohn ‘s  complaint 2016 part 1  opinion and medical  operation. J Crohns Colitis 2017; 11 3 – 25.
9. Sandborn WJ, Su C, Beach BE, et al. Tofacitinib as induction and  conservation  remedy for ulcerative colitis. N Engl J Med 2017; 376 1723 – 36.
10. Sandborn WJ, Su C, Panes J Tofacitinib as induction and  conservation  remedy for ulcerative colitis. N Engl J Med 2017; 377 496 – 7.
11. Wang Y, Parker CE, Bhanji T, Feagan BG, MacDonald JK Oral 5 aminosalicylic acid for induction of absolution in ulcerative colitis. Cochrane Database Syst Rev 2016; 4 CD000543.
12. Wang Y, Parker CE, Feagan BG, MacDonald JK Oral 5- aminosalicylic acid for  conservation of absolution in ulcerative colitis. Cochrane Data base Syst Rev 2016 CD000544.
13. Williams JG, Alam MF, Alrubaiy L, et al. Infliximab versus ciclosporin for steroid resistant acute severe ulcerative colitis( CONSTRUCT) a mixed  styles, open marker,  realistic randomised trial. Lancet Gastroenterol Hepatol 2016; 1 15 – 24.
14. Dignass AU, Gasche C, Bettenworth D, et al. European  agreement on the  opinion and  operation of iron  insufficiency and anaemia in  seditious bowel  conditions. J Crohns Colitis 2015; 9 211 – 22.
15. Choi CH, Rutter MD, Atari A, et al. Forty-time analysis of colon osmotic eavesdrop shaft program for neoplasm in ulcerative colitis: an updated overview. Am J Gastroenterology 2015; 110 1022–34.
16. Losurdo G, Iannone A, Contralto A, Ierardi E, Di Leo A, Principi M Escherichia coli Issue 1917 in ulcerative colitis treatment methodical review and meta-analysis. J Gastrointestinal Liver This 2015; 24 499–505.
17. Van der Woude CJ, Ardizzone S, Bengtson MB, et al. The alternate European substantiated- grounded agreement on reduplication and pregnancy in seditious bowel complaint. J Crohn's Colitis 2015; 9 107–24.
18. Anne V, Beaugerie L, Egan L, et al. European substantiation- grounded agreement on seditious bowel complaint and malice. J Crohn's Colitis 2015; 9 945–65.
19. Query M, Pineton de Chambrun G, Stefanescu C, et al. Discovery of dysplasia or cancer in 3.5 of cases with seditious bowel disease and colonic strictures. Clin Gastroenterol Hepatol 2015; 13 1770–5.
20. Ores land T, Bemelman WA, Sampietro GM, et al. European evidence grounded agreement on surgery for ulcerative colitis. J Crohn's Colitis 2015; 9 4–25.
21. Sand born WE, Danese S, D‘Hans G, et al. Induction of clinical and colonoscope absolution of mild- to-moderate ulcerative colitis with budesonide MMX 9 mg pooled analysis of two phase 3 studies. Nourishment Pharma col The 2015; 41 409–18.
22. Rapier OF, Magro F, Abreu C, et al. Alternate European substantiation- grounded agreement on the forestalled, opinion and operation of opportunistic infections in matory bowel complaint. J Crohn's Colitis 2014; 8 443–68.
23. Levine A, Koletzko S, Turner D, et al. EOGHAN revised Porto criteria for the opinion of seditious bowel complaint in children and adolescents. J Mediate Gastroenterology Nut 2014; 58 795–806.
24. Uhlig HH, Schwerd T, Koletzko S, et al. The individual approach to monogenic veritably early onset seditious bowel complaint. Gastroenterology 2014; 147 990–1007. e3.
25. Sand born WE, Feagan BG, Marano C, et al. Subcutaneous golimumab induces clinical response and absolution in cases with moderate- to severe ulcerative colitis. Gastroenterology 2014; 146 85–95; quiz e14 – 5.
26. Feagan BG, Rutgers P, Beach BE, et al. Vedolizumab as induction and maintenance remedy for ulcerative colitis. N EGL J Med 2013; 369 699–710.
27. Ford AC, Khan KJ, Achkar JP, Moated P efficacy of oral vs. topical, or combined oral and topical 5- amino salicylates, in Ulcerative Colitis methodical review and meta-analysis. Am J Gastroenterology 2012; 107 167–76; author reply 77.
28. Marshall JK, Theban M, Steinhart AH, Newman JR, Anand A, Irvine EJ Rectal 5- amino salicylic acid for conservation of absolution in ulcerative colitis. Cochrane Database Syst Rev 2012; 11 CD004118.
29. Feagan BG, Macdonald JK Oral 5- amino salicylic acid for conservation of absolution in ulcerative colitis. Cochrane Database Syst Rev 2012; 10 CD000544.
30. Wittig R, Albers L, Koletzko S, Saam J, Tries caravan Pediatric habitual seditious bowel complaint in a German statutory health INSURANCE – prevalence rates from 2009 to 2012. J Mediate Gastroenterology Nut 2019; 68 244–50.
31. Sand born WE, van Assche G, Reinisch W, et al. Adalimumab induces and maintains clinical absolution in cases with moderate- to severe ulcerative colitis. Gastroenterology 2012; 142 257–65. e1 – 3.
32. Solberg IC, Lygren I, Jahnsen J, et al. Clinical course during the first 10 times of ulcerative colitis results from a population-based commencement cohort(IBSEN Study). Scand J Gastroenterol 2009; 44 431–40.
33. Stange EF, Travis SPL, Vermeire S, Reinisch W, Geboes K, Barakaus kine A et al. European substantiation- grounded Consensus on the opinion and operation of ulcerative colitis Delineations and opinion. J Crohn’s Colitis 2008; 2 1–23.
34. Biancone L, Michetti P, Travis S, Escher JC, Moser G, Forbes A et al. European substantiation- grounded consensus on the operation of ulcerative colitis Special situations. J Crohn’s Colitis 2008; 2 63–92.
35. D'Hans G, Baert F, Van AG, Caenepeel P, Verge P, Gunman H et al. Beforehand combined immunosuppression or conventional management in cases with recently diagnosed Crohn’s complaint an open randomized trial. Lancet 2008; 371 660–7.
36. Toruner M, Loftus EV, Jr., Harmsen WS, Zinsmeister AR, Orenstein R, Sand born WE et al. Threat factors for opportunistic infections in cases with seditious bowel complaint. Gastroenterology 2008; 134 929–36.
37. Travis SPL, Stage EF, Lehmann M, Ireland T, Perelman WA, Showers Y et al. European substantiation- grounded consensus on the operation of ulcerative colitis. Current operation. J Crohn’s Colitis 2008; 2 24–62.
38. Baumgart DC, Sand born WE seditious bowel complaint clinical aspects and established and evolving curatives. Lancet 2007; 3691641–57.
39. Baumgart DC, Carding SR. Inflammatory bowel complaint cause and immunology. Lancet 2007; 369 1627–40.
40. Xavier RJ, Podolsky DK unraveling the pathogenesis of inflamed rightist bowel complaint. Nature 2007; 448 427–34.